Secondary Outcomes
thrombotic, bleeding
BLEEDING, SECONDARY
Overall, 354 participants (74.5%) in the P2Y12 inhibitor group and 339 participants (72.4%) in the usual care group survived to hospital discharge (median aOR, 1.15; 95% CrI, 0.84-1.55; posterior probability of superiority, 80.8%). Data on thrombotic, bleeding, and other key secondary outcomes are provided in 